Moderna, Inc. $MRNA Shares Sold by Douglas Lane & Associates LLC

Douglas Lane & Associates LLC cut its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 13.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,160,945 shares of the company's stock after selling 182,534 shares during the period. Moderna makes up approximately 2.7% of Douglas Lane & Associates LLC's holdings, making the stock its 5th biggest position. Douglas Lane & Associates LLC owned 0.29% of Moderna worth $223,563,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the company. BlackRock Inc. acquired a new position in Moderna in the second quarter worth about $2,142,877,000. Theleme Partners LLP bought a new position in shares of Moderna in the second quarter valued at approximately $564,272,000. Wellington Management Group LLP grew its position in Moderna by 4.4% during the 2nd quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company's stock worth $172,384,000 after acquiring an additional 103,977 shares during the last quarter. Merck & Co. Inc. bought a new position in Moderna in the 2nd quarter valued at $161,642,545. Finally, Bamco Inc. NY acquired a new position in Moderna in the second quarter worth $139,317,000. Institutional investors own 75.33% of the company's stock.

Insider Buying and Selling

In other Moderna news, insider Shannon Klinger sold 3,471 shares of the company's stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total value of $485,766.45. Following the transaction, the insider directly owned 74,129 shares of the company's stock, valued at $10,374,353.55. This represents a 4.47% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Jamey Mock sold 34,836 shares of Moderna stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total value of $4,685,093.64. Following the sale, the chief financial officer directly owned 59,375 shares of the company's stock, valued at $7,985,343.75. This represents a 36.98% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 118,882 shares of company stock valued at $16,862,280. Insiders own 10.80% of the company's stock.

Moderna Stock Performance

NASDAQ MRNA traded up $22.04 on Friday, hitting $219.03. 17,695,772 shares of the stock were exchanged, compared to its average volume of 12,174,882. The business's fifty day moving average is $136.67 and its 200 day moving average is $83.94. Moderna, Inc. has a 52 week low of $22.28 and a 52 week high of $219.31. The company has a market capitalization of $87.45 billion, a PE ratio of -27.44 and a beta of 1.09. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, topping analysts' consensus estimates of ($2.03) by $0.06. The business had revenue of $145.00 million during the quarter, compared to analysts' expectations of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.Moderna's quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the company posted ($2.13) earnings per share. Research analysts anticipate that Moderna, Inc. will post -6.09 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on MRNA. Deutsche Bank Aktiengesellschaft began coverage on Moderna in a report on Friday, August 28th. They set a "hold" rating on the stock. Jefferies Financial Group reiterated a "hold" rating on shares of Moderna in a report on Wednesday, August 19th. Royal Bank Of Canada reissued a "sector perform" rating and set a $130.00 price objective on shares of Moderna in a research note on Wednesday, August 19th. Piper Sandler reaffirmed an "overweight" rating on shares of Moderna in a research note on Monday, August 3rd. Finally, Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Moderna in a research note on Friday, September 25th. Seven equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and five have given a Sell rating to the company's stock. According to data from MarketBeat.com, Moderna presently has a consensus rating of "Hold" and a consensus price target of $78.17.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Nasdaq-100 reentry may drive additional demand. Moderna is scheduled to rejoin the Nasdaq-100 before the October 9 market open, replacing Warner Bros. Discovery. The inclusion follows a substantial rise in Moderna’s market capitalization and could prompt buying by index-tracking funds, providing a near-term technical tailwind. Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock?
• Positive Sentiment: Investors are increasingly focused on Moderna’s cancer opportunity. Moderna and Merck are expanding development of the individualized neoantigen therapy intismeran autogene, also known as V940 or mRNA-4157, including studies in melanoma and other cancers. The collaboration with Tempus is intended to support potential commercialization and strengthens the long-term oncology narrative. Tempus Announces Multi-Year Collaboration with Moderna and Merck
• Positive Sentiment: Manufacturing capabilities are becoming a key part of the bull case. Recent coverage highlights Moderna’s efforts to apply lessons from its COVID-era production network to manufacture future cancer therapies at commercial scale. Successful execution could improve confidence in the company’s ability to convert its pipeline into revenue. Moderna's Next Test: Manufacturing a Cancer Franchise at Scale
• Neutral Sentiment: Analyst sentiment remains cautious. Morgan Stanley reportedly assigned Moderna a “Hold” rating, suggesting that the recent rally may already reflect substantial optimism about the oncology pipeline and index inclusion. Moderna Gets a Hold from Morgan Stanley
• Negative Sentiment: Execution and valuation risks are rising after the surge. Commentary emphasizes that scaling cancer manufacturing will be a major test, while reports that insiders are trimming holdings could add to concerns that the stock has moved ahead of near-term fundamentals. Moderna Builds the Back Office for a Cancer Franchise as Insiders Trim Holdings

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease, supporting the company's work across infectious diseases, immuno-oncology, rare diseases, autoimmune conditions, and cardiovascular diseases.

Moderna's commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.